
Shares of consumer health company Kenvue KVUE.N rise 20.2% to $17.27 premarket
Kimberly-Clark KMB.O says it will acquire the Tylenol maker in a deal valued at about $48.7 billion
Separately, co reports Q3 adj. EPS of 28 cents vs Wall Street estimates of 27 cents - LSEG data
Up to last close, stock was down ~33% YTD